| 摘要 |
<p>The present invention refers to novel ophthalmic compositions for topical application having a proven stability, which main active principle is a protein component capable of blocking the cytokine activity or factors involved in ophthalmic processes of the inflammatory, and angiogenic types or in acute tissue rejection. Pro-inflammatory cytokines are closely related to the alpha TNF, and VEGF as a powerful angiogenic agent, so that compositions having a protein active principle are highly useful since the biological activity of said two cytokines is neutralized. Active proteins may act as natural or recombinant monoclonal or polyclonal antibodies, or biologically active fragments therefrom which comprise Fv, Fab, F(ab')2 or scFv, said proteins being capable of avoiding or reducing the phenomenon related to biological tissue transplant rejection, particularly ocular tissue, including cornea.</p> |
